What is the appropriate next diagnostic step for a 37‑year‑old woman with painful, rapidly enlarging lumbar subcutaneous nodules (≈1 cm and 4 cm), not visible on the skin but palpable, and associated idiopathic urticaria, chronic lymphadenopathy, fatigue, and steroid‑responsive pain?

Urgent Excisional Biopsy Required

Given the rapidly enlarging, painful subcutaneous nodules (1 cm and 4 cm) in the lumbar region with associated systemic symptoms (chronic lymphadenopathy, fatigue, urticaria), you must obtain an excisional biopsy immediately to rule out subcutaneous panniculitis-like T-cell lymphoma (SPTCL) or other aggressive cutaneous lymphomas.

Diagnostic Approach

The combination of painful, rapidly enlarging subcutaneous nodules with chronic lymphadenopathy and systemic symptoms raises serious concern for cutaneous lymphoma, particularly SPTCL, which presents as "solitary or multiple subcutaneous nodules to indurated plaque-like lesions" 1. The steroid-responsive pain is concerning rather than reassuring—SPTCL can initially respond to steroids but requires definitive diagnosis 2.

Critical Differential Diagnoses to Exclude:

High-risk malignant conditions:

• Subcutaneous panniculitis-like T-cell lymphoma (SPTCL): CD3+, CD4–, CD8+, typically TCRαβ+ phenotype. When associated with hemophagocytic syndrome, 5-year survival drops to 46% versus 91% without it 2
• Primary cutaneous gamma/delta T-cell lymphoma: More aggressive variant
• Extranodal NK/T-cell lymphoma: Can present with subcutaneous nodules and systemic symptoms 1

Benign but important conditions:

• Subcutaneous sarcoidosis (though typically painless) 3
• Rheumatoid nodules (but would expect joint symptoms) 4
• Granuloma annulare (typically less symptomatic) 5

Immediate Workup Required

1. Excisional Biopsy (Not Fine Needle Aspiration)

Perform excisional biopsy of the larger 4 cm nodule to obtain adequate tissue for:

• Routine histology with H&E staining
• Comprehensive immunohistochemistry panel: CD3, CD4, CD8, CD56, TCRαβ (betaF1), TCRγδ, CD30, CD20, CD79a, cytotoxic proteins (TIA-1, granzyme B, perforin)
• T-cell receptor (TCR) gene rearrangement analysis to assess clonality
• Flow cytometry if fresh tissue available

Fine needle aspiration is insufficient—cutaneous lymphomas require architectural assessment and extensive immunophenotyping 6.

2. Staging Investigations (Perform Concurrently)

Blood work:

• Complete blood count with manual differential (look for atypical lymphocytes)
• Comprehensive metabolic panel, LDH (elevated in aggressive lymphomas)
• Flow cytometry of peripheral blood for abnormal T-cell populations
• TCR gene rearrangement of peripheral blood if lymphocytosis present

Imaging:

• FDG-PET/CT scan of entire body: Essential for PCLs with subcutaneous presentation to evaluate extent of disease 6. Note that chronic wounds and reactive lymph nodes may show uptake, but combined PET/CT helps clarify significance
• If PET unavailable: CT chest/abdomen/pelvis with contrast

Lymph node assessment:

• Given chronic lymphadenopathy, any node ≥1.5 cm or firm/irregular requires ultrasound-guided core biopsy or excisional biopsy 6

3. Bone Marrow Biopsy

Required for cutaneous lymphomas with intermediate or aggressive clinical behavior, particularly given the systemic symptoms and lymphadenopathy 6.

Critical Pitfalls to Avoid

1. Do not delay biopsy for imaging: Obtain tissue diagnosis immediately while staging workup proceeds in parallel

2. Do not perform only superficial punch biopsy: Subcutaneous lesions require excisional or deep incisional biopsy to capture the full depth of involvement 2

3. Do not assume benign disease based on steroid response: SPTCL can initially respond to immunosuppression but requires definitive diagnosis, as treatment differs dramatically—systemic steroids or immunosuppressive agents for SPTCL without hemophagocytic syndrome versus aggressive chemotherapy if hemophagocytic syndrome develops 2

4. Do not attribute symptoms solely to urticaria: The constellation of rapidly enlarging nodules, lymphadenopathy, and fatigue suggests systemic disease beyond simple chronic urticaria 7

Urgency Justification

The rapid enlargement (particularly the 4 cm lesion), pain, and systemic symptoms distinguish this from indolent conditions. SPTCL without hemophagocytic syndrome has excellent prognosis (91% 5-year survival) with appropriate treatment, but delays in diagnosis risk progression to hemophagocytic syndrome (46% 5-year survival) 2. Early tissue diagnosis is essential for mortality reduction.

Refer immediately to dermatology and hematology/oncology for coordinated evaluation within 1-2 weeks maximum.